MSLE

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced four poster presentations at the 31st Annual Congress of the World Muscle Society (WMS). The Congress will take place in Hiroshima, Japan, from Sept. 29 to Oct. 3, 2026. Details of the scientific posters at WMS: Date & Time: Wednesday, Sept. 30, 5:15-6:15 p.m. JST Poster 2.74P: BASECAMP: A Phase 2a Dose Comparison and Exploratory Efficacy Study of Forazapadin (SAT-3247) in Ambulatory Boys with Duchenne Muscular Dystrophy Presenter: Anne M. Connolly, MD, Chief of t

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced the assignment of the International Nonproprietary Name (INN) "forazapadin" for the Company's orally administered, small molecule drug candidate designed to restore muscle regeneration that was previously known as SAT-3247. "As we continue to execute our clinical development strategies, this naming designation reflects the maturity of the program and supports its future development as we plan for regulatory submission and commercialization in Duchenne muscular dystrophy,

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that management will participate in the following investor conferences in September. 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9, 2026Presentation: 3:55 p.m. EDTLocation: New York, NYWebcast: here H.C. Wainwright 28th Annual Global Investment ConferenceDate: Wednesday, September 16, 2026 Fireside chat: 9 a.m. EDTLocation: New York, NYWebcast: here Members of the Satellos leadership team will be available for one-on-one investor meetings du

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

SUPPL - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerability profile, stable strength and improved quality of life reported in six-month follow-up data in TRAILHEAD Phase 2 adult DMD studyCompany remains on track to report clinical data from Phase 2 BASECAMP pediatric DMD study in Q4 2026Strong financial position with $61.8 million in cash, cash equivalents and short-term investments as of June 30, 2026, expected to provide runway through 2027SAT-3247 granted FDA Fast Track Designation for DMD TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Satellos B

F-X - Satellos Bioscience Inc. (0001421642) (Subject)

F-10 - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

All four participants showed a decline in fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle composition All four participants showed an increase in TE99C, a measure of maximum effort in upper limbs, with a mean improvement of approximately 34% from a baseline of 16.1 joules/kg to 21.6 joules/kg at TRAILHEAD month 6, suggesting enhanced upper limb activityNear doubling of handgrip strength measured during the 28-day CL-101 study maintained through month 6 of TRAILHEADMean creatine kinase (CK), a biomarker of muscle damage, declined 38% from baseline through month 6 of TRAILHEADSafety profile of SAT

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy ("Duchenne" or "DMD")Fast Track is designed to expedite the development/review of new drugs to treat serious or life-threatening conditions and fill unmet medical needsPhase 2 BASECAMP and TRAILHEAD studies ongoing in DMD with additional data expected in 2H 2026 TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fas

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that new data from its SAT-3247 clinical development program will be featured at the 19th International Congress on Neuromuscular Diseases (ICNMD), taking place July 7–11, 2026, in Florence, Italy, at Fortezza da Basso. Presentations will include a poster highlighting six-month follow-up data from participants who completed the Phase 1b SAT-3247-CL-101 trial and enrolled in the ongoing Phase 2 TRAILHEAD (LT-001) trial. Satellos will also participate

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the results of its Annual Meeting of Shareholders held June 17, 2026 (the "Meeting"). Satellos is pleased to announce that all the nominees listed in the management information circular dated May 14, 2026 (the "Circular") were elected as directors. Shareholders present at the Meeting or represented by proxy totaled 55.3% of the issued and outstanding common shares of the Company. The results of the vote are detailed below: DirectorVotes Fo

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that members of the Company management team will participate in the following investor conferences in June. Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Presentation: 11:05 a.m.Location: New York, NY Oppenheimer CNS & Neuro-Muscular SummitDate: Wednesday, June 10Panel: Next-Generation Therapeutics in Genetic Muscle Disorders, 10:15 a.m.Location: Miami, FL The presentation will be available via live webcast on the Event

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to complete enrollment in Q3 2026The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027 TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026. "The first quarter of